Radiation Therapy CDDP With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with cisplatin and fluorouracil may kill more tumor cells. It is not yet known whether radiation therapy and cisplatin are more effective with or without fluorouracil in treating patients with head and neck cancer.
PURPOSE: This randomized phase III trial is studying radiation therapy and cisplatin to compare how well they work with or without fluorouracil in treating patients with stage III or stage IV head and neck cancer.
| Condition | Intervention | Phase |
|---|---|---|
|
Head and Neck Cancer |
Drug: cisplatin Drug: fluorouracil Radiation: radiation therapy |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Phase III Randomized Trial Comparing Single Agent Cisplatin With the Combination of 5-Fluorouracil and Cisplatin, Concurrent With Radiation Therapy in Stage III and IV Squamous Cell Head and Neck Cancer |
- Clinical Response-complete disappearance of detectable tumor [ Time Frame: at 12 weeks after completing chemoradiotherapy ] [ Designated as safety issue: No ]Twelve weeks after completing chemoradiotherapy, a formal evaluation for response will be made, to include a careful evaluation by the head and neck surgeon, medical and radiation oncologists, and, as appropriate, a radiologic and an endoscopic examination. Patients will be considered to have achieved either a clinical complete response (i.e. complete disappearance of all clinically and radiologically detectable tumor) or to have clinical persistent disease.
- Pathologic (Final) Response [ Time Frame: after surgery ] [ Designated as safety issue: No ]A Pathologic, or final response will be assigned to patients after any salvage surgery is performed for clinical persistent disease, and after planned neck dissection in those achieving a clinical complete response. If no surgery is performed after chemoradiotherapy, the clinical and the pathologic (final) response will be the same. Patient will be coded as having either a pathologic complete response, or as having pathologic persistent disease.
- Disease Recurrence [ Time Frame: at recurrence ] [ Designated as safety issue: No ]Patients with any new evidence of cancer after achieving a complete response are considered to have recurrent disease. Biopsy verification will be obtained if at all possible and salvage surgery is recommended if possible.
| Enrollment: | 69 |
| Study Start Date: | January 2008 |
| Primary Completion Date: | March 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Arm I
Patients undergo full-dose radiotherapy once or twice daily 5 days a week for up to 7 weeks and receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy.
|
Drug: cisplatin
Given IV
Other Name: CDDP
Radiation: radiation therapy
Patients undergo full-dose radiotherapy once or twice daily 5 days a week for up to 7 weeks
Other Name: radiation
|
|
Experimental: Arm II
Patients undergo radiotherapy as in arm I and receive fluorouracil IV and cisplatin IV continuously on days 1-4 and 22-25 of radiotherapy.
|
Drug: cisplatin
Given IV
Other Name: CDDP
Drug: fluorouracil
Given IV
Other Name: fluorouracil
Radiation: radiation therapy
Patients undergo full-dose radiotherapy once or twice daily 5 days a week for up to 7 weeks
Other Name: radiation
|
Detailed Description:
OBJECTIVES:
- To compare the relapse-free survival of patients treated with radiotherapy and cisplatin with vs without fluorouracil.
- To compare the overall survival, local control without surgery, and patterns of failure in patients treated with these regimens.
- To compare the acute and long-term toxicity of these regimens in these patients.
- To compare the quality of life of patients treated with these regimens.
- To prospectively collect biopsy material, mucosal scrapings, and serum in an effort to generate hypotheses for future correlative studies.
OUTLINE: This is a multicenter study. Patients are stratified according to radiotherapy schedule (once daily vs twice daily) and radiotherapy planning (2D vs 3D vs intensity-modulated radiotherapy). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients undergo full-dose radiotherapy once or twice daily 5 days a week for up to 7 weeks and receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy.
- Arm II: Patients undergo radiotherapy as in arm I and receive fluorouracil IV and cisplatin IV continuously on days 1-4 and 22-25 of radiotherapy.
Patients with biopsy-verified residual disease at the primary site or local recurrence after achieving a complete response to chemoradiotherapy may undergo salvage surgery 12 weeks after the completion of chemoradiotherapy.
Patients complete questionnaires periodically to assess late toxicity and quality of life.
After completion of study treatment, patients are followed periodically.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx
- No histologic diagnosis other than squamous cell carcinoma
- A primary site must be identified
Must have locoregionally confined stage III (excluding T1-2, N1) or stage IV disease
- No evidence of nodal disease below the clavicles or distant hematogenous metastases (M0)
- No stage IVC disease (stage IVB disease allowed)
Deemed appropriate for definitive non-operative management with curative intent
- Resectable disease is not required
- No primary cancer of the nasopharynx, paranasal sinus, or salivary gland
PATIENT CHARACTERISTICS:
- ECOG performance status 0-1
- WBC > 3,500/mm³
- Platelet count > 100,000/mm³
- Serum creatinine < 2.0 mg/dL
- Alkaline phosphatase < 2 times normal
- AST < 2 times normal
- Bilirubin ≤ 2.0 mg/dL
- Serum calcium normal
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No unstable or uncontrolled angina
- No clinically apparent jaundice
- No active infection
- No history of any other malignancy (except squamous cell or basal cell skin cancer or cervical carcinoma in situ), unless the patient has been continuously disease-free for at least 5 years
- Not a poor compliance risk
- Able to withstand the rigors of intensive treatment
- Available for and compliant with adequate long-term follow-up
PRIOR CONCURRENT THERAPY:
- No prior definitive surgery or radiotherapy for this malignancy
- No prior chemotherapy, immunotherapy, or epidermal growth factor receptor inhibitors for any disease Patients who have had previous definitive surgery, or radiation therapy for this malignancy, and patients who have had any previous chemotherapy, immunotherapy, or EGF receptor inhibition for any disease are ineligible.
Exclusion Criteria Patients with primary cancers of the nasopharynx, paranasal sinus or salivary gland are ineligible.
Patients with unstable or uncontrolled angina, clinically apparent jaundice, or active infection are ineligible.
Patients with a history of any other malignancy (except squamous or basal cell skin cancer or cervical carcinoma in-situ) are ineligible, unless the patient has been continuously disease-free for at least 5 years.
Patients with any histologic diagnosis other than squamous cell carcinoma are ineligible.
Patients who might be a poor-compliance risk are ineligible.
Pregnant or breastfeeding women are ineligible. Women/men of reproductive potential must be willing to practice acceptable methods of birth control to prevent pregnancy.
Contacts and Locations| United States, Ohio | |
| Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center | |
| Cleveland, Ohio, United States, 44106-5065 | |
| Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center | |
| Cleveland, Ohio, United States, 44195 | |
| Principal Investigator: | David J. Adelstein, MD | Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center |
| Principal Investigator: | Panayiotis Savvides, MD | Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center |
More Information
Additional Information:
No publications provided
| Responsible Party: | Case Comprehensive Cancer Center |
| ClinicalTrials.gov Identifier: | NCT00608205 History of Changes |
| Other Study ID Numbers: | CASE3307, P30CA043703, NCI-2010-01197 |
| Study First Received: | January 30, 2008 |
| Last Updated: | October 30, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Case Comprehensive Cancer Center:
|
stage III squamous cell carcinoma of the hypopharynx stage III squamous cell carcinoma of the lip and oral cavity stage III squamous cell carcinoma of the oropharynx stage III squamous cell carcinoma of the larynx |
stage IV squamous cell carcinoma of the hypopharynx stage IV squamous cell carcinoma of the lip and oral cavity stage IV squamous cell carcinoma of the oropharynx stage IV squamous cell carcinoma of the larynx |
Additional relevant MeSH terms:
|
Head and Neck Neoplasms Neoplasms by Site Neoplasms Cisplatin Fluorouracil Antineoplastic Agents Therapeutic Uses Pharmacologic Actions |
Radiation-Sensitizing Agents Physiological Effects of Drugs Antimetabolites Molecular Mechanisms of Pharmacological Action Antimetabolites, Antineoplastic Immunosuppressive Agents Immunologic Factors |
ClinicalTrials.gov processed this record on June 17, 2013